Morgan Stanley brokers say the explosion of interest in the weight loss drugs will be far bigger than first thought. And these major companies could get hit.
Already a subscriber?Australia’s supermarket giants and fast-food chains may need to brace for a hit to customer demand as the adoption of diabetes and weight-loss drugs like Ozempic accelerates.
Morning Stanley warns Woolworths and Coles were exposed to the potential changes in national eating habits.the world by storm last year, sending shares of drug developer Novo Nordisk and competitor Eli Lilly soaring asIn the new report, the investment bank’s analysts told clients that they predicted the still-nascent weight-loss drug market would grow to $US105 billion by 2030, up from a previous estimate of $US77 billion.
The promise of easier access to weight-loss treatments prompted investors to flee ASX-listed health-tech developers in droves last year,Shares in both companies have since recovered, and – contrary to last year’s sell-off – the report said that ResMed’s key sleep apnoea market did not look at risk from the rise of weight-loss drugs in the near future.
More broadly, the investment bank forecasts demand for the drugs in Australia to be the highest in the Asia Pacific region – given the nation’s higher rates of obesity – and could penetrate as much as 40 per cent of the market by the early 2030s – from just 0.7 per cent today.And if the drugs become that widespread, Morgan Stanley predicts it could have effects outside healthcare. “Australia is the only market where our consumer team expects a moderate impact,” the report said.
Australia Latest News, Australia Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
ASX 200 LIVE: ASX to slip, Wall St edges lowerAustralian shares are set to follow New York with a modest opening loss. Citi sees ‘profit-taking’ risk for ASX 200. Bitcoin rallies. Follow updates here.
Read more »
ASX: global equity rally could push ASX 200 to reset recordHopes of rate cuts from major central banks in the first half of the year are continuing to buoy equity markets, making this week’s local inflation data pivotal for investor sentiment.
Read more »
ASX 200 LIVE: ASX to slip, US equities reset record highsShares are set to edge lower; US equities reset record highs; gold, oil ease; Reddit leaps on debut, while Apple slumps on lawsuit; ANZ sees iron ore floor. Follow updates here.
Read more »
SIG ASX: Chemist Warehouse records surging sales, profits ahead of ASX debutThe results were detailed in a financial update from Sigma Healthcare, with which it intends to merge. The deal still requires regulatory approval.
Read more »
ASX 200 LIVE: ASX to rise, S&P 500 resets record highASX futures add 0.6pc, Fed policymakers reiterate rates cut are approaching. $A rallies, bitcoin rebounds. Gold jumps. Follow updates here.
Read more »
ASX 200 LIVE: ASX to rise, Wall Street rallies broadly ahead of Federal Reserve policy statementAustralian shares are set to open higher after all three US benchmarks advanced. Nvidia erases early losses. Bitcoin slumps. Follow updates here.
Read more »